KalVista Pharmaceuticals, Inc.
KALVDelisted Jun 11, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348911
KalVista Pharmaceuticals, Inc. was delisted on Jun 11, 2026; its insiders filed their last Form 4 on Jun 11, 2026; 184 institutions reported holding it in 13F filings for Q1 2026, worth $1.39B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:52 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 |
| Filing | 10-KT/A | 10-K | 10-K | 10-K | 10-K |
| Reported | Jul 10, 2025 | Jul 11, 2024 | Jul 10, 2023 | Jul 7, 2022 | Jul 13, 2021 |
| Operating expenses | $188.0M | $140.4M | $110.9M | $96.6M | $57.9M |
| Research and development | $71.7M | $86.2M | $80.3M | $70.2M | $41.3M |
| Selling, general and administrative | $116.3M | $54.3M | $30.6M | $26.4M | $16.6M |
| Operating income | -$188.0M | -$140.4M | -$110.9M | -$96.6M | -$57.9M |
| Income tax | $3.39M | $0 | $0 | $0 | $0 |
| Net income | -$183.4M | -$126.6M | -$92.9M | -$82.3M | -$46.2M |
| EPS, basic | $-3.69 | $-3.44 | $-3.33 | $-3.36 | – |
| EPS, diluted | $-3.69 | $-3.44 | $-3.33 | $-3.36 | – |
| Weighted shares, basic | 49.7M | 36.8M | 27.9M | 24.5M | – |
| Weighted shares, diluted | 49.7M | 36.8M | 27.9M | 24.5M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 |
| Filing | 10-KT | 10-K | 10-K | 10-K | 10-K |
| Reported | Jul 10, 2025 | Jul 11, 2024 | Jul 10, 2023 | Jul 7, 2022 | Jul 13, 2021 |
| Cash and equivalents | $131.6M | $31.8M | $56.2M | $30.7M | $50.6M |
| Total current assets | $241.7M | $225.7M | $172.3M | $193.6M | $264.3M |
| Property, plant and equipment | $1.99M | $2.23M | $2.95M | $2.18M | $1.79M |
| Total assets | $250.8M | $235.4M | $183.2M | $203.9M | $272.0M |
| Accounts payable | $4.88M | $9.11M | $4.82M | $3.64M | $1.98M |
| Total current liabilities | $45.2M | $22.8M | $15.0M | $11.6M | $9.77M |
| Total liabilities | $155.4M | – | – | – | – |
| Shareholders' equity | $95.4M | $206.6M | $161.0M | $185.1M | $257.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 |
| Filing | 10-KT | 10-K | 10-K | 10-K | 10-K |
| Reported | Jul 10, 2025 | Jul 11, 2024 | Jul 10, 2023 | Jul 7, 2022 | Jul 13, 2021 |
| Operating cash flow | -$152.9M | -$89.2M | -$75.3M | -$78.1M | -$30.2M |
| Capital expenditures | $434.0K | $42.0K | $1.20M | $931.0K | $82.0K |
| Free cash flow | -$153.3M | -$89.3M | -$76.5M | -$79.1M | -$30.3M |
| Depreciation and amortization | $941.0K | $816.0K | $718.0K | $564.0K | $537.0K |
| Stock-based compensation | $12.3M | $21.9M | $9.92M | $11.1M | $7.12M |
| Investing cash flow | $91.0M | -$84.7M | $41.4M | $57.9M | -$147.7M |
| Financing cash flow | $159.7M | $150.7M | $58.1M | $1.58M | $212.1M |
| Net change in cash | $100.5M | -$24.4M | $25.5M | -$19.9M | $34.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 7, 2026 | 53.2M | +6.6% | SEC |
| Mar 18, 2026 | 51.2M | +3.0% | SEC |
| Nov 3, 2025 | 50.5M | +2.3% | SEC |
| Aug 29, 2025 | 50.5M | +16.9% | SEC |
| Jun 25, 2025 | 50.0M | +16.9% | SEC |
| Mar 7, 2025 | 49.7M | +17.8% | SEC |
| Dec 4, 2024 | 49.4M | +43.0% | SEC |
| Aug 26, 2024 | 43.2M | +25.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.